Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Influenza Vaccine in Gammopathy
NCT02267733Phase 1Completed
- Sponsor
- Yale University
- Start
- Oct 2014
- Primary completion
- Dec 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of influenza virus vaccine, split virion in influenza (2 arms), sponsored by Yale University. Primary endpoint: Rate of Disease Control at 10 months. Started Oct 2014; status: completed.
02
Drugs
influenza virus vaccine, split virion
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02267733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02267733.